Henderson Morley Announces New Application From Anti-Viral Platform Technology

Apr 04, 2001, 01:00 ET from Henderson Morley plc

    LONDON, April 4 /PRNewswire/ -- The Board of Henderson Morley is pleased
 to report that following extensive research the directors believe that its
 technology ICVT (Ionic Contra-Viral Therapy) is showing excellent laboratory
 results in tests on cell cultures.
     The United States Food and Drug Administration has indicated that subject
 to a satisfactory IND application, ICVT may be a suitable candidate for Phase
 2 clinical trials.  The company is currently considering a number of potential
 evaluation licence applications and Material Transfer Agreements from
 pharmaceutical companies.
     In addition, scientists at Henderson Morley have discovered that the
 technology shows good results on more applications than originally expected.
     One of these new applications is for the treatment of herpes in cats.  It
 is believed that Feline herpes affects a significant number of un-vaccinated
 cats and can recur over their life.  There are currently no drugs available to
 treat the infection.  In the USA alone, there are over 60 million cats and the
 European companion pet market is believed to be one of the fastest growing
 veterinary markets.
     Commenting Chairman Andrew Knight said:  "We are very excited at the
 results being shown in the lab for ICVT.  We have always believed that this is
 a platform technology which could have many applications and we look forward
 to progressing the first of these as soon as possible."
 
     This announcement has been prepared by and is the sole responsibility of
 the Directors of Henderson Morley plc.  Grant Thornton, which is regulated by
 the Institute of Chartered Accountants in England and Wales, has approved this
 announcement for the purposes of Section 57 of the Financial Services Act
 1986.  Grant Thornton is acting as financial adviser to Henderson Morley plc
 and to no-one else and will not be responsible to anyone other than Henderson
 Morley plc for providing the protections afforded to customers of Grant
 Thornton or for providing advice in relation to any investment made pursuant
 to this announcement.
 
 

SOURCE Henderson Morley plc
    LONDON, April 4 /PRNewswire/ -- The Board of Henderson Morley is pleased
 to report that following extensive research the directors believe that its
 technology ICVT (Ionic Contra-Viral Therapy) is showing excellent laboratory
 results in tests on cell cultures.
     The United States Food and Drug Administration has indicated that subject
 to a satisfactory IND application, ICVT may be a suitable candidate for Phase
 2 clinical trials.  The company is currently considering a number of potential
 evaluation licence applications and Material Transfer Agreements from
 pharmaceutical companies.
     In addition, scientists at Henderson Morley have discovered that the
 technology shows good results on more applications than originally expected.
     One of these new applications is for the treatment of herpes in cats.  It
 is believed that Feline herpes affects a significant number of un-vaccinated
 cats and can recur over their life.  There are currently no drugs available to
 treat the infection.  In the USA alone, there are over 60 million cats and the
 European companion pet market is believed to be one of the fastest growing
 veterinary markets.
     Commenting Chairman Andrew Knight said:  "We are very excited at the
 results being shown in the lab for ICVT.  We have always believed that this is
 a platform technology which could have many applications and we look forward
 to progressing the first of these as soon as possible."
 
     This announcement has been prepared by and is the sole responsibility of
 the Directors of Henderson Morley plc.  Grant Thornton, which is regulated by
 the Institute of Chartered Accountants in England and Wales, has approved this
 announcement for the purposes of Section 57 of the Financial Services Act
 1986.  Grant Thornton is acting as financial adviser to Henderson Morley plc
 and to no-one else and will not be responsible to anyone other than Henderson
 Morley plc for providing the protections afforded to customers of Grant
 Thornton or for providing advice in relation to any investment made pursuant
 to this announcement.
 
 SOURCE  Henderson Morley plc